bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S3 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S3
Supplementary Tables 1-6 and Supplementary Figures 1-6 from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Authors: Stopsack Konrad H. , Nandakumar Subhiksha , Wibmer Andreas G. , Haywood Samuel , Weg Emily S. , Barnett Ethan S. , Kim Chloe J. , Carbone Emily A. , Vasselman Samantha E. , Nguyen Bastien , Hullings Melanie A. , Scher Howard I. , Morris Michael J. , Solit David B. , Schultz Nikolaus , Kantoff Philip W. , Abida Wassim
Published: April 2023

All supplementary tables and figures
Supplementary Data from Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Authors: Stopsack Konrad H. , Nandakumar Subhiksha , Wibmer Andreas G. , Haywood Samuel , Weg Emily S. , Barnett Ethan S. , Kim Chloe J. , Carbone Emily A. , Vasselman Samantha E. , Nguyen Bastien , Hullings Melanie A. , Scher Howard I. , Morris Michael J. , Solit David B. , Schultz Nikolaus , Kantoff Philip W. , Abida Wassim
Published: April 2023

All tumor-level alteration data with OncoKB annotation (mutations, copy number changes, fusions)
Supplementary Figures from EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Authors: Lheureux Stephanie , Oaknin Ana , Garg Swati , Bruce Jeffrey P. , Madariaga Ainhoa , Dhani Neesha C. , Bowering Valerie , White Justin , Accardi Sarah , Tan Qian , Braunstein Marsela , Karakasis Katherine , Cirlan Iulia , Pedersen Stephanie , Li Tiantiam , Fariñas-Madrid Lorena , Lee Yeh Chen , Liu Zhihui (Amy) , Pugh Trevor J. , Oza Amit M.
Published: April 2023

Supplementary figures S1-S5
Table S3 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Authors: Basler Lucas , Gabryś Hubert S. , Hogan Sabrina A. , Pavic Matea , Bogowicz Marta , Vuong Diem , Tanadini-Lang Stephanie , Förster Robert , Kudura Ken , Huellner Martin W. , Dummer Reinhard , Guckenberger Matthias , Levesque Mitchell P.
Published: April 2023

Summary of patient outcome of the individual groups (without landmark analysis) 95% confidence intervals were provided in parentheses. PP-only patients were the best performing group, with a similar outcome compared to responding patients. TPD-only patients presented a significantly worse OS of 9 vs. 30 months in the PP-only group (p=0.001, FWER=0.007). Patients with mixed PP&TPD were in between both other groups.
Figure S3 from Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Authors: Basler Lucas , Gabryś Hubert S. , Hogan Sabrina A. , Pavic Matea , Bogowicz Marta , Vuong Diem , Tanadini-Lang Stephanie , Förster Robert , Kudura Ken , Huellner Martin W. , Dummer Reinhard , Guckenberger Matthias , Levesque Mitchell P.
Published: April 2023

Distribution of pseudoprogression and true progression and association with OS, PFS and iPFS (no landmark).
Supplementary Data from Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Authors: Lee Soo-Chin , Shimasaki Noriko , Lim Joline S.J. , Wong Andrea , Yadav Kritika , Yong Wei Peng , Tan Lip Kun , Koh Liang Piu , Poon Michelle L.M. , Tan Sing Huang , Ow Samuel G.W. , Bharwani Lavina , Yap Yoon Sim , Foo Mabel Z.Q. , Coustan-Smith Elaine , Sundar Raghav , Tan Hon Lyn , Chong Wan Qin , Kumarakulasinghe Nesaretnam Barr , Lieow Jedidah L.M. , Koe Priscillia J.X. , Goh Boon Cher , Campana Dario
Published: April 2023

Supplementary Materials, Figures
Kraman et al Supplementary Data from FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
Authors: Kraman Matthew , Faroudi Mustapha , Allen Natalie L. , Kmiecik Katarzyna , Gliddon Daniel , Seal Claire , Koers Alexander , Wydro Mateusz M. , Batey Sarah , Winnewisser Julia , Young Lesley , Tuna Mihriban , Doody Jacqueline , Morrow Michelle , Brewis Neil
Published: April 2023

Kraman et al Supplementary figures
Supplementary Figures from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Authors: El Sissy Carine , Kirilovsky Amos , Van den Eynde Marc , Muşină Ana-Maria , Anitei Maria-Gabriela , Romero Alfredo , Marliot Florence , Junca Audelaure , Doyen Jérôme , Mlecnik Bernhard , Haicheur Nacilla , Fredriksen Tessa , Lagorce Christine , Jouret-Mourin Anne , Leonard Daniel , Bibeau Frédéric , Iseas Soledad , Roca Enrique L. , Cabanne Ana M. , Vaccaro Carlos A. , Santino Juan P. , Huertas Eduardo , Tougeron David , Carvalho Carlos , Figueiredo Nuno , Perez Rodrigo O. , Habr-Gama Angelita , Scripcariu Viorel , Gerard Jean-Pierre , Galon Jérôme , Zeitoun Guy , Pagès Franck
Published: April 2023

Supplementary Figures
Figure S2 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Figure S2. Outcomes of induction regimens excluding subjects in the conventional-dose cohort receiving a 2nd induction course.
Figure S1 from Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia
Authors: Wei Hui , Wang Ying , Gale Robert Peter , Lin Dong , Zhou Chunlin , Liu Bingcheng , Qiu Shaowei , Gu Runxia , Li Yan , Zhao Xingli , Wei Shuning , Gong Benfa , Liu Kaiqi , Gong Xiaoyuan , Liu Yuntao , Zhang Guangji , Song Zhen , Wang Yang , Li Wei , Mi Yingchang , Wang Jianxiang
Published: April 2023

Figure S1. A CONSORT diagram about induction therapy
Supplementary Fig 4 from Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma
Authors: Paradis Justine S. , Acosta Monica , Saddawi-Konefka Robert , Kishore Ayush , Lubrano Simone , Gomes Frederico , Arang Nadia , Tiago Manoela , Coma Silvia , Wu Xingyu , Ford Kyle , Day Chi-Ping , Merlino Glenn , Mali Prashant , Pachter Jonathan A. , Sato Takami , Aplin Andrew E. , Gutkind J. Silvio
Published: April 2023

Supplementary Figure S4. MEKi/FAKi combination reduces B2905 syngeneic cells growth in allograft tumor models.
Supplementary Figure 2 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Authors: Ryan Meagan B. , Fece de la Cruz Ferran , Phat Sarah , Myers David T. , Wong Edmond , Shahzade Heather A. , Hong Catriona B. , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S2. KRASG12C inhibitors are subject to adaptive feedback through activation of RTKs.
Supplementary Tables from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

Supplementary Table 1. Predicted biological function of TP53 mutations detected in ALK-rearranged non-small cell lung cancer patients Supplementary Table 2. Baseline charcteristics of ALK-rearranged non-small cell lung cancer patients with and without TP53 mutations Supplementary Table 3. Predicted biological function of ATM mutations detected in ALK-rearranged non-small cell lung cancer patients
Supplementary Figure 3 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Authors: Liu Chen , Lu Hengyu , Wang Hongyun , Loo Alice , Zhang Xiamei , Yang Guizhi , Kowal Colleen , Delach Scott , Wang Ye , Goldoni Silvia , Hastings William D. , Wong Karrie , Gao Hui , Meyer Matthew J. , Moody Susan E. , LaMarche Matthew J. , Engelman Jeffrey A. , Williams Juliet A. , Hammerman Peter S. , Abrams Tinya J. , Mohseni Morvarid , Caponigro Giordano , Hao Huai-Xiang
Published: April 2023

CSF1R-driven SHP2-dependent MAPK signaling in GDM-1 cells and SHP2 dependency of the viability in M-CSF-stimulated monocytes in the T cell co-culture assay, and the in vivo combination benefit in suppressing tumor associated macrophage by anti-PD-1 antibody and TNO155 in MC38 tumors.
Supplementary Figure 2 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Authors: Liu Chen , Lu Hengyu , Wang Hongyun , Loo Alice , Zhang Xiamei , Yang Guizhi , Kowal Colleen , Delach Scott , Wang Ye , Goldoni Silvia , Hastings William D. , Wong Karrie , Gao Hui , Meyer Matthew J. , Moody Susan E. , LaMarche Matthew J. , Engelman Jeffrey A. , Williams Juliet A. , Hammerman Peter S. , Abrams Tinya J. , Mohseni Morvarid , Caponigro Giordano , Hao Huai-Xiang
Published: April 2023

The synergy in the MAPK pathway suppression and anti-proliferation effect by KRASG12C inhibitor and TNO155.
Supplementary Fig. S7 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

A Mcl-1 inhibitor alone shows less toxicity A, Cell viability determined after 72 hours by MTT assay in A925L cells and H2228 cells which were treated with S63845. Data shown are representative of at least three independent experiments. The data shown are the mean {plus minus} SEM of triplicate cultures. B, H2228 cells stained for calcein-AM and DCS1 which were exposed to DMSO, alectinib (3â€‰âµmol/L), S63845 (1â€‰âµmol/L), or concurrent treatment for 72 hours. Scale bars, 100 âµm. E, Quantification of number of calcein-AM+ or DCS1+ H2228 cells determined by fluorometer. Results are mean {plus minus} SEM of three independent experiments. *, P < 0.05
Supplementary Figure 1 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Authors: Liu Chen , Lu Hengyu , Wang Hongyun , Loo Alice , Zhang Xiamei , Yang Guizhi , Kowal Colleen , Delach Scott , Wang Ye , Goldoni Silvia , Hastings William D. , Wong Karrie , Gao Hui , Meyer Matthew J. , Moody Susan E. , LaMarche Matthew J. , Engelman Jeffrey A. , Williams Juliet A. , Hammerman Peter S. , Abrams Tinya J. , Mohseni Morvarid , Caponigro Giordano , Hao Huai-Xiang
Published: April 2023

Identification of the feedback activated RTK and the synergy in anti-proliferation effect by the combination of respective RTK inhibitors and dabrafenib plus trametinib in RKO and MDST8 cells.
Supplementary Table-6 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

6A. Classification accuracy of CMS 4 samples on training data set V1 using 4-fold cross validation as function of number of genes. 6B. Classification accuracy of CMS 4 samples on validation data set (V2) as function of number of genes. 6C. Classification accuracy CMS 4 samples with out of sample prediction set (V2o) as function of number of genes. 6D. Classification accuracy CMS 3 samples with TCGA dataset (RAN-seq subset) as function of number of genes. 6E. Classification accuracy of CMS 3 samples with Affymetrix data set (V2a) as function of number of genes.
Supplementary Table-5 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

5A. Classification accuracy of CMS 3 samples on training data set V1 using 4-fold cross validation as function of number of genes. 5B.Classification accuracy of CMS 3 samples on validation data set (V2) as function of number of genes. 5C. Classification accuracy CMS3 samples with out of sample prediction set (V2o) as function of number of genes. 5D. Classification accuracy CMS 3 samples with TCGA dataset (RAN-seq subset) as function of number of genes. 5E. Classification accuracy CMS3 samples with Affymetrix dataset (V2a) as function of number of genes.
Supplementary Table-2 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Classification accuracy of different modelling strategies on training data set (V1) using 4-fold cross validation.
Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Digital droplet PCR (ddPCR) testing for single mutation in dilution series. (A) The observed VAFs of HapMap serial dilutions measured by using a ddPCR assay for a single mutation (with three replicates) vs. the expected VAFs; (B) The representative ddPCR raw data and fluorescence intensity thresholds for determining positive or negative droplets.
Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Overview schematic of MRD assay. MRD assay workflow from characterizing a primary tumor to determining if a blood draw contains evidence of residual disease.
Supplementary Figure 13 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Patients who were recurrence free after treatment for early stage breast cancer. cfDNA time points for all patients who did not experienced recurrence. Those marked with poor detection limits had an estimated detection limit worse than 1/1,000. End points represent time of last follow up or death.
Supplementary Figure-2 from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Classification accuracy for training data V1 (based on 4-fold cross val-idation, 2A) and the full validation data V2 (2B) for various methods as function of number
Supplementary Data from Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting
Authors: Morris Jeffrey S. , Luthra Rajyalakshmi , Liu Yusha , Duose Dzifa Y. , Lee Wonyul , Reddy Neelima G. , Windham Justin , Chen Huiqin , Tong Zhimin , Zhang Baili , Wei Wei , Ganiraju Manyam , Broom Bradley M. , Alvarez Hector A. , Mejia Alicia , Veeranki Omkara , Routbort Mark J. , Morris Van K. , Overman Michael J. , Menter David , Katkhuda Riham , Wistuba Ignacio I. , Davis Jennifer S. , Kopetz Scott , Maru Dipen M.
Published: April 2023

Supplementary methods and results
Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Authors: Parsons Heather A. , Rhoades Justin , Reed Sarah C. , Gydush Gregory , Ram Priyanka , Exman Pedro , Xiong Kan , Lo Christopher C. , Li Tianyu , Fleharty Mark , Kirkner Gregory J. , Rotem Denisse , Cohen Ofir , Yu Fangyan , Fitarelli-Kiehl Mariana , Leong Ka Wai , Hughes Melissa E. , Rosenberg Shoshana M. , Collins Laura C. , Miller Kathy D. , Blumenstiel Brendan , Trippa Lorenzo , Cibulskis Carrie , Neuberg Donna S. , DeFelice Matthew , Freeman Samuel S. , Lennon Niall J. , Wagle Nikhil , Ha Gavin , Stover Daniel G. , Choudhury Atish D. , Getz Gad , Winer Eric P. , Meyerson Matthew , Lin Nancy U. , Krop Ian , Love J. Christopher , Makrigiorgos G. Mike , Partridge Ann H. , Mayer Erica L. , Golub Todd R. , Adalsteinsson Viktor A.
Published: April 2023

Supplementary Methods
Table S4 from Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia
Authors: Tang Lu , Wu Jianghua , Li Cheng-Gong , Jiang Hui-Wen , Xu Min , Du Mengyi , Yin Zhinan , Mei Heng , Hu Yu
Published: April 2023

Table S4 shows survival analysis of selective immune signatures in OS and EFS.
Supplementary Video S1 from Interventional Radiology for Local Immunotherapy in Oncology
Authors: Tselikas Lambros , Champiat Stephane , Sheth Rahul A. , Yevich Steve , Ammari Samy , Deschamps Frederic , Farhane Siham , Roux Charles , Susini Sandrine , Mouraud Severine , Delpla Alexandre , Raoult Thibault , Robert Caroline , Massard Christophe , Barlesi Fabrice , Soria Jean-Charles , Marabelle Aurélien , de Baere Thierry
Published: April 2023

Intratumoral injection techniques
Supplementary Figure S2 from Interventional Radiology for Local Immunotherapy in Oncology
Authors: Tselikas Lambros , Champiat Stephane , Sheth Rahul A. , Yevich Steve , Ammari Samy , Deschamps Frederic , Farhane Siham , Roux Charles , Susini Sandrine , Mouraud Severine , Delpla Alexandre , Raoult Thibault , Robert Caroline , Massard Christophe , Barlesi Fabrice , Soria Jean-Charles , Marabelle Aurélien , de Baere Thierry
Published: April 2023

Techniques to tag the injected tumor
Figure S3 from Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
Authors: Powles Ryan L. , Wali Vikram B. , Li Xiaotong , Barlow William E. , Nahleh Zeina , Thompson Alastair M. , Godwin Andrew K. , Hatzis Christos , Pusztai Lajos
Published: April 2023

Supplementary Figure 3. Pre- and Post-treatment biopsy cellularity for each patient in the SWOG S0800 cohort. The dotted line indicates the selected cut off for retaining samples in pre-post analysis.
Supplementary Figure Legend from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
Authors: Cleary James M. , Wang Victoria , Heist Rebecca S. , Kopetz E. Scott , Mitchell Edith P. , Zwiebel James A. , Kapner Kevin S. , Chen Helen X. , Li Shuli , Gray Robert J. , McShane Lisa M. , Rubinstein Larry V. , Patton David R. , Meric-Bernstam Funda , Dillmon Melissa S. , Williams P. Mickey , Hamilton Stanley R. , Conley Barbara A. , Aguirre Andrew J. , O'Dwyer Peter J. , Harris Lyndsay N. , Arteaga Carlos L. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure Legend
Supplementary Figure S6 from Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial
Authors: Asleh Karama , Brauer Heather Ann , Sullivan Amy , Lauttia Susanna , Lindman Henrik , Nielsen Torsten O. , Joensuu Heikki , Thompson E. Aubrey , Chumsri Saranya
Published: April 2023

Supplementary Figure S6 shows the expression levels of 41 single genes associated with capecitabine benefit or resistance against recurrence status
Supplementary Material from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Authors: Thorat Mangesh A. , Levey Pauline M. , Jones J. Louise , Pinder Sarah E. , Bundred Nigel J. , Fentiman Ian S. , Cuzick Jack
Published: April 2023

Additional study design information, figures and tables, and supplementary references
Supplementary Figure 1 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Authors: Thorat Mangesh A. , Levey Pauline M. , Jones J. Louise , Pinder Sarah E. , Bundred Nigel J. , Fentiman Ian S. , Cuzick Jack
Published: April 2023

Supplementary Figure 1 summarizes the treatment allocation in the UK/ANZ DCIS trial, and distribution of patients in the biomarker study subset (BSS1).
REMARK checklist from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
Authors: Thorat Mangesh A. , Levey Pauline M. , Jones J. Louise , Pinder Sarah E. , Bundred Nigel J. , Fentiman Ian S. , Cuzick Jack
Published: April 2023

REMARK checklist referring to current accepted word version of the manuscript.
Table S1 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Authors: Lichtman Eben I. , Du Hongwei , Shou Peishun , Song Feifei , Suzuki Kyogo , Ahn Sarah , Li Guangming , Ferrone Soldano , Su Lishan , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Clinical details associated with primary AML patient samples
Supplemental Methods from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Authors: Lichtman Eben I. , Du Hongwei , Shou Peishun , Song Feifei , Suzuki Kyogo , Ahn Sarah , Li Guangming , Ferrone Soldano , Su Lishan , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Supplemental Methods
Appendix from A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer
Authors: Bhatia Smita , Palomares Melanie R. , Hageman Lindsey , Chen Yanjun , Landier Wendy , Smith Kandice , Umphrey Heidi , Reich Caroline A. , Zamora Kathryn W. , Armenian Saro H. , Bevers Therese B. , Blaes Anne , Henderson Tara , Hodgson David , Hudson Melissa M. , Korde Larissa A. , Melin Susan A. , Merajver Sofia D. , Overholser Linda , Pruthi Sandhya , Wong F. Lennie , Garber Judy E.
Published: April 2023

Appendix
Figure S4 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Authors: Lichtman Eben I. , Du Hongwei , Shou Peishun , Song Feifei , Suzuki Kyogo , Ahn Sarah , Li Guangming , Ferrone Soldano , Su Lishan , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

B7-H3.CAR-Ts control leukemia growth in additional xenograft model using OCI-AML2 cells
Figure S3 from Preclinical Evaluation of B7-H3–specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
Authors: Lichtman Eben I. , Du Hongwei , Shou Peishun , Song Feifei , Suzuki Kyogo , Ahn Sarah , Li Guangming , Ferrone Soldano , Su Lishan , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Comparison of B7-H3 expression with B7-H3.CAR-T cytotoxicity.
Supplementary Data 2 from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Authors: Peng Zhi , Wei Jia , Wang Feng , Ying Jieer , Deng Yanhong , Gu Kangsheng , Cheng Ying , Yuan Xianglin , Xiao Juxiang , Tai Yanfei , Wang Linna , Zou Jianjun , Zhang Yanqiao , Shen Lin
Published: April 2023

Protocol
Supplementary Table 1 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

The table shows the characteristics of patients treated on the PAC/SIR/TAC phase I trial.
Supplementary Figure S1 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Authors: Demetri George D. , Luke Jason J. , Hollebecque Antoine , Powderly John D. , Spira Alexander I. , Subbiah Vivek , Naumovski Louie , Chen Chris , Fang Hua , Lai Dominic W. , Yue Huibin , Polepally Akshanth R. , Purcell James W. , Robinson Randy , Sharma Padmanee , Allison James P. , Tolcher Anthony , Villalobos Victor M.
Published: April 2023

Supplementary Figure S1 shows the study design.
Supplementary Figure 4 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results
Authors: Pidala Joseph , Walton Kelly , Elmariah Hany , Kim Jongphil , Mishra Asmita , Bejanyan Nelli , Nishihori Taiga , Khimani Farhad , Perez Lia , Faramand Rawan G. , Davila Marco L. , Nieder Michael L. , Sagatys Elizabeth M. , Holtan Shernan G. , Lawrence Nicholas J. , Lawrence Harshani R. , Blazar Bruce R. , Anasetti Claudio , Sebti Said M. , Betts Brian C.
Published: April 2023

Impact of JAK2/mTOR blockade on human NK cell function and proliferation. A) Graph shows the cytolytic activity ({plus minus}SEM) of NK cells after 4 hours of culture with K562 target cells, while exposed to DMSO, ruxolitinib (lμM), pacritinib (1.25μM), sirolimus 10ng/ml, or a combination of pacritinib plus sirolimus. B) Human NK cells (105 ) were stimulated with a cytokine cocktail of recombinant human (rh) IL-2 (200 IU/ml) and rhll-15 (10 ng/ml), in the presence of DMSO, ruxolitinib, pacritinib, sirolimus, or pacritinib plus sirolimus. Drugs were added once on day 0. Cytokines were replenished on day +3. Bar graph shows NK cell proliferation ({plus minus}SEM) on day +5 of the culture using a colorimetric assay.
Supplementary table 6 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Authors: Scott Aaron T. , Weitz Michelle , Breheny Patrick J. , Ear Po Hien , Darbro Benjamin , Brown Bart J. , Braun Terry A. , Li Guiying , Umesalma Shaikamjad , Kaemmer Courtney A. , Maharjan Chandra K. , Quelle Dawn E. , Bellizzi Andrew M. , Chandrasekharan Chandrikha , Dillon Joseph S. , O'Dorisio Thomas M. , Howe James R.
Published: April 2023

Supplementary table 6
Supplementary table 5 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Authors: Scott Aaron T. , Weitz Michelle , Breheny Patrick J. , Ear Po Hien , Darbro Benjamin , Brown Bart J. , Braun Terry A. , Li Guiying , Umesalma Shaikamjad , Kaemmer Courtney A. , Maharjan Chandra K. , Quelle Dawn E. , Bellizzi Andrew M. , Chandrasekharan Chandrikha , Dillon Joseph S. , O'Dorisio Thomas M. , Howe James R.
Published: April 2023

Supplementary table 5
Supplementary table 2 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Authors: Scott Aaron T. , Weitz Michelle , Breheny Patrick J. , Ear Po Hien , Darbro Benjamin , Brown Bart J. , Braun Terry A. , Li Guiying , Umesalma Shaikamjad , Kaemmer Courtney A. , Maharjan Chandra K. , Quelle Dawn E. , Bellizzi Andrew M. , Chandrasekharan Chandrikha , Dillon Joseph S. , O'Dorisio Thomas M. , Howe James R.
Published: April 2023

Supplementary table 2
Supplementary Data from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

Supplementary Figures, Tables and Data
Supplementary table 1 from Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
Authors: Scott Aaron T. , Weitz Michelle , Breheny Patrick J. , Ear Po Hien , Darbro Benjamin , Brown Bart J. , Braun Terry A. , Li Guiying , Umesalma Shaikamjad , Kaemmer Courtney A. , Maharjan Chandra K. , Quelle Dawn E. , Bellizzi Andrew M. , Chandrasekharan Chandrikha , Dillon Joseph S. , O'Dorisio Thomas M. , Howe James R.
Published: April 2023

Supplementary table 1
Supplementary Data 6 from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

Enrichment of transcription factor consensus binding motifs in regulatory elements predictive of gene expression associated with poor overall survival.
Supplementary Data 5 from Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma
Authors: Barwick Benjamin G. , Gupta Vikas A. , Matulis Shannon M. , Patton Jonathan C. , Powell Doris R. , Gu Yanyan , Jaye David L. , Conneely Karen N. , Lin Yin C. , Hofmeister Craig C. , Nooka Ajay K. , Keats Jonathan J. , Lonial Sagar , Vertino Paula M. , Boise Lawrence H.
Published: April 2023

Regulatory elements predictive of gene expression for genes prognostic of overall survival in CoMMpass.
Appendix 1 from Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Authors: Sheng Xinan , Yan Xieqiao , Wang Lin , Shi Yanxia , Yao Xin , Luo Hong , Shi Benkang , Liu Jiyan , He Zhisong , Yu Guohua , Ying Jianming , Han Weiqing , Hu Changlu , Ling Yun , Chi Zhihong , Cui Chuanliang , Si Lu , Fang Jianmin , Zhou Aiping , Guo Jun
Published: April 2023

Protocol of study
Table S4 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Cox regression multivariate analysis assessing correlation of SIP with OS (A) and PFS (B) after adjustment for known prognostic factors
Figure S9 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

PD-1 expression on circulating SIP+ T-cells in the overall ICI cohort (A) and in progressing or non-progressing patients (B)
Figure S7 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Overall response rate and disease clinical benefit according to SIP status in the ICI validation cohort
Figure S6 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Progression free survival and overall survival according to SIP status in the ICI discovery (A) and validation (B) cohorts
Figure S5 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Optimization of SIP cut-off according to maximization of log-likelihood ratio method (A). Variation of HR for PFS (blue line) according to circulating senescent lymphocytes (% CD28- CD57+ KLRG1+ among CD8+ T-cells) (B) (ICI discovery cohort)
Figure S4 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

SIP median level in the ICI discovery, ICI validation and PCT cohorts
Figure S10 from Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
Authors: Ferrara Roberto , Naigeon Marie , Auclin Edouard , Duchemann Boris , Cassard Lydie , Jouniaux Jean-Mehdi , Boselli Lisa , Grivel Jonathan , Desnoyer Aude , Mezquita Laura , Texier Matthieu , Caramella Caroline , Hendriks Lizza , Planchard David , Remon Jordi , Sangaletti Sabina , Proto Claudia , Garassino Marina C. , Soria Jean-Charles , Marabelle Aurelien , Voisin Anne-Laure , Farhane Siham , Besse Benjamin , Chaput Nathalie
Published: April 2023

Variation of SIP in the overall ICI cohort and in progressing and non-progressing patients (A). Variation of immunosenescence markers (CD28 absence, CD57 expression, KLRG1 expression) on CD4 and CD8+ T-cells and variation of circulating TEMRA, naïve or TC1 CD8+ T-cells in the overall ICI cohort and in progressing and non-progressing patients (B)
Supplementary Data from Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Johnson Douglas B. , Zhao Fengmin , Noel Marcus , Riely Gregory J. , Mitchell Edith P. , Wright John J. , Chen Helen X. , Gray Robert J. , Li Shuli , McShane Lisa M. , Rubinstein Larry V. , Patton David , Williams P. Mickey , Hamilton Stanly R. , Conley Barbara A. , Arteaga Carlos L. , Harris Lyndsay N. , O'Dwyer Peter J. , Chen Alice P. , Flaherty Keith T.
Published: April 2023

Supplementary Figure 7: (A) PFS and (B) OS of patients based on presence of concurrent mutation in NRAS, KRAS, or HRAS.
Supplementary Table 5 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Authors: Semaan Alexander , Bernard Vincent , Lee Jaewon J. , Wong Justin W. , Huang Jonathan , Swartzlander Daniel B. , Stephens Bret M. , Monberg Maria E. , Weston Brian R. , Bhutani Manoop S. , Chang Kyle , Scheet Paul A. , Maitra Anirban , Jakubek Yasminka A. , Guerrero Paola A.
Published: April 2023

Aneuploidy, TMB, Complexity Score, HRD_LST, HRD_LOH, and SCNA for individual samples, correlation of SCNA markers, and platinum response.
Supplementary Table 2 from Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples
Authors: Semaan Alexander , Bernard Vincent , Lee Jaewon J. , Wong Justin W. , Huang Jonathan , Swartzlander Daniel B. , Stephens Bret M. , Monberg Maria E. , Weston Brian R. , Bhutani Manoop S. , Chang Kyle , Scheet Paul A. , Maitra Anirban , Jakubek Yasminka A. , Guerrero Paola A.
Published: April 2023

Mutations called in matched samples comparing enriched vs. FFPE samples (n=2) and enriched vs. non-enriched samples (n=1)
Supplementary Figure S5 from Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Authors: Nguyen Tan-Trieu , Ramsay LeeAnn , Ahanfeshar-Adams Mozhdeh , Lajoie Mathieu , Schadendorf Dirk , Alain Tommy , Watson Ian R.
Published: April 2023

Supp Figure S5. Tumor growth of parental B16-F10 and B16-F10 Jak2 KOs after virus injection
Table S1 from Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Authors: Iorgulescu J. Bryan , Gokhale Prafulla C. , Speranza Maria C. , Eschle Benjamin K. , Poitras Michael J. , Wilkens Margaret K. , Soroko Kara M. , Chhoeu Chhayheng , Knott Aine , Gao Yan , Lim-Fat Mary Jane , Baker Gregory J. , Bonal Dennis M. , Nguyen Quang-Dé , Grant Gareth R. L. , Ligon Keith L. , Sorger Peter K. , Chiocca E. Antonio , Anderson Ana C. , Kirschmeier Paul T. , Sharpe Arlene H. , Freeman Gordon J. , Reardon David A.
Published: April 2023

Table S1
Figure S1 from Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Authors: Iorgulescu J. Bryan , Gokhale Prafulla C. , Speranza Maria C. , Eschle Benjamin K. , Poitras Michael J. , Wilkens Margaret K. , Soroko Kara M. , Chhoeu Chhayheng , Knott Aine , Gao Yan , Lim-Fat Mary Jane , Baker Gregory J. , Bonal Dennis M. , Nguyen Quang-Dé , Grant Gareth R. L. , Ligon Keith L. , Sorger Peter K. , Chiocca E. Antonio , Anderson Ana C. , Kirschmeier Paul T. , Sharpe Arlene H. , Freeman Gordon J. , Reardon David A.
Published: April 2023

Figure S1
Figure S2 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Authors: Noordhoek Iris , Treuner Kai , Putter Hein , Zhang Yi , Wong Jenna , Meershoek-Klein Kranenbarg Elma , Duijm-de Carpentier Marjolijn , van de Velde Cornelis J.H. , Schnabel Catherine A. , Liefers Gerrit-Jan
Published: April 2023

Predictive performance by BCI (H/I) groups based on RFI in pN0 (N=241) and pN+ (N=664) patients.
Figure S1 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Authors: Noordhoek Iris , Treuner Kai , Putter Hein , Zhang Yi , Wong Jenna , Meershoek-Klein Kranenbarg Elma , Duijm-de Carpentier Marjolijn , van de Velde Cornelis J.H. , Schnabel Catherine A. , Liefers Gerrit-Jan
Published: April 2023

Forest plot and bar graph of predictive performance of BCI (H/I) in the Overall cohort (N=908) and the Primary AI subset (N=794).
Supplementary Data from Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients
Authors: Bhargava Hersh K. , Leo Patrick , Elliott Robin , Janowczyk Andrew , Whitney Jon , Gupta Sanjay , Fu Pingfu , Yamoah Kosj , Khani Francesca , Robinson Brian D. , Rebbeck Timothy R. , Feldman Michael , Lal Priti , Madabhushi Anant
Published: April 2023

Supplementary Information
Table 1 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Authors: Nayak Lakshmi , Molinaro Annette M. , Peters Katherine , Clarke Jennifer L. , Jordan Justin T. , de Groot John , Nghiemphu Leia , Kaley Thomas , Colman Howard , McCluskey Christine , Gaffey Sarah , Smith Timothy R. , Cote David J. , Severgnini Mariano , Yearley Jennifer H. , Zhao Qing , Blumenschein Wendy M. , Duda Dan G. , Muzikansky Alona , Jain Rakesh K. , Wen Patrick Y. , Reardon David A.
Published: April 2023

Data table
Supplementary Table 2 from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Authors: Nayak Lakshmi , Molinaro Annette M. , Peters Katherine , Clarke Jennifer L. , Jordan Justin T. , de Groot John , Nghiemphu Leia , Kaley Thomas , Colman Howard , McCluskey Christine , Gaffey Sarah , Smith Timothy R. , Cote David J. , Severgnini Mariano , Yearley Jennifer H. , Zhao Qing , Blumenschein Wendy M. , Duda Dan G. , Muzikansky Alona , Jain Rakesh K. , Wen Patrick Y. , Reardon David A.
Published: April 2023

Study data
Supplementary figures, S1 to S14 from A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry
Authors: Son Minsoo , Kim Hongbeom , Han Dohyun , Kim Yoseop , Huh Iksoo , Han Youngmin , Hong Seung-Mo , Kwon Wooil , Kim Haeryoung , Jang Jin-Young , Kim Youngsoo
Published: April 2023

raw figure files, for just in case
Supplementary Table S1-S4 from Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer
Authors: Hui Edwin Pun , Ma Brigette B.Y. , Lam W.K. Jacky , Chan K.C. Allen , Mo Frankie , Ai Qi-yong Hemis , King Ann D. , Wong Chi Hang , Wong Kenneth C.W. , Lam Daisy C.M. , Tong Macy , Poon Darren M.C. , Li Leung , Lau Thomas K.H. , Wong Kwan Hung , Lo Y.M. Dennis , Chan Anthony T.C.
Published: April 2023

Supplementary Table S1-S4
Supplementary Figure S1-S2 from Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer
Authors: Hui Edwin Pun , Ma Brigette B.Y. , Lam W.K. Jacky , Chan K.C. Allen , Mo Frankie , Ai Qi-yong Hemis , King Ann D. , Wong Chi Hang , Wong Kenneth C.W. , Lam Daisy C.M. , Tong Macy , Poon Darren M.C. , Li Leung , Lau Thomas K.H. , Wong Kwan Hung , Lo Y.M. Dennis , Chan Anthony T.C.
Published: April 2023

Supplementary Figure S1-S2
Figure S3 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Authors: Gandhi Shipra , Pandey Manu R. , Attwood Kristopher , Ji Wenyan , Witkiewicz Agnieszka K. , Knudsen Erik S. , Allen Cheryl , Tario Joseph D. , Wallace Paul K. , Cedeno Carlos D. , Levis Maria , Stack Suzanne , Funchain Pauline , Drabick Joseph J. , Bucsek Mark J. , Puzanov Igor , Mohammadpour Hemn , Repasky Elizabeth A. , Ernstoff Marc S.
Published: April 2023

Multispectral staining of the immune cell infiltrate in melanoma. A, Low power magnification depicting marked variability in the immune cell types. B, Higher magnification showing PDL1 expression on melanoma cells (arrow) and multiple m-MDSCs in contact with melanoma and CD8+ T cells. C, PD-L1 expressing melanoma cells (arrows) are infiltrated by PMN-MDSCs, regulatory T cells, CD4+ T helper cells and CD8+ cytotoxic T cells. D, PD-L1 negative melanoma with CD8+ cytotoxic T cells, T helper cells and m-MDSCs.